Proud to announce that I received ERC Stg & wellcome trust awards to start my group. I have however declined both in favour of a position in the private sector where I am able to do innovative & impactful science in a way that best fits my personal circumstances & ambitions.

@oded

Glad to see concrete steps being taken to fix publishing issues. One reason I enjoy my current role in industry: I still get to publish with great academic teams, but my career doesn’t depend entirely on it—and neither does the development of young researchers in my team.

Surprising finding that standard chemo treatment induces resistance to menin inhibitors in AML. Published in @ISEHSociety journal Exp. Hem:

Excited to see BoneMarrowMap out in press! Please check out the R package (now capable of classifying 100,000 hematopoietic cells in 10 minutes) and consider giving the paper a read for some insights into how differentiation goes wrong in AML!

Thanks for flagging @Adrien_Jolly_ . Quantification of cell cycling is definitely not trivial - when we looked at the cycling numbers in HSPCs in the literature they were all over the place.

I no longer recommend academic careers for people from working class backgrounds. Hard to get to a financially stable position when you dont have additional means to make up for such low salaries. Academic science can be fun, but lets drop the pretence that it's inclusive.

Alert Stromal Cell Marvels, my newly established group at Uniklinik Freiburg, is seeking a student for a Master/PhD project. If you are interested in stromal cell-immune cell interaction at the borders of the CNS and beyond – drop me a message.

tidyplots is an R package to generate publication-ready plots for scientific papers https://t.co/NUMfIyJ7Wi #rstats

Blood is a window on systems health. Great work from Higgins and colleagues @Nature shows that stability or setpoints in complete blood count parameters in 10s of thousands of patients over 20 years is associated with clinical risk and all cause mortality https://t.co/XZeO71ykIK

Thanks for highlighting this really important effort to develop new prognostic criteria for new therapies. Have to do this for all new therapies, can’t assume that risk stratification systems developed for other therapies are relevant. More input and refinement to this is needed!

Unbound by formats or JIF - eLife is now completely upsetting the way science results are shared through short reports. No more story-crafting, no more eternal revisions. PhDs may actually start graduating with a published paper. Get ready to get scooped by reports on eLife.

A great opportunity available at Servier for anyone interested in applying AI approaches to disease modelling https://t.co/vZm8TSf8Dc

I’m excited to share an R package that we’ve created for mapping scRNA-seq data across normal and malignant hematopoiesis! We've used this to identify hematopoietic stem cells from healthy tissues and map leukemia cells from hundreds of patients. 1/6 https://t.co/NW4aMMFUsx

This is friggin useful! Thanks Weike!!!

scplotter provides a set of functions to visualize single-cell sequencing data in an easy and efficient way. https://t.co/zq0laaHcRQ

A new bank of >2000 scientific/medical images and icons for free use in figures and presentations just released by @NIAIDNews @NIH. Very useful for early career researchers who can’t afford @BioRender https://t.co/rfcWhJLnL6

🚨 Preprint alert! Our new work uncovering that glutathione (GSH) boosts tumor growth by supplying amino acids is now available at @bioRxiv! Check it out 👇🏼and follow along for the #tweetorial (1/10) https://t.co/RpyACVbufW

Really good training block with 165kg squat, 100kg bench and 210kg (soft lockout) deadlift. Onwards and upwards @ScientistsLift #scientistswholift

Very frustrating to hear that all these fantastic new medicines exist but patients aren't getting access to them.

Plenty of fun ways to do science - academia isn't the only show in town